CDK4/6i reverses MEIS2 inhibition of CRL4(CRBN) and promotes BCMA loss to enhance IMiD/CELMoD therapy in multiple myeloma.

Journal: Blood neoplasia •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Huang X, Jayabalan D, Di Liberto M, et al. (2026). "CDK4/6i reverses MEIS2 inhibition of CRL4(CRBN) and promotes BCMA loss to enhance IMiD/CELMoD therapy in multiple myeloma.". Blood neoplasia. https://doi.org/10.1016/j.bneo.2026.100285